Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China flag China · Delayed Price · Currency is CNY
4.360
+0.230 (5.57%)
Nov 13, 2026, 3:04 PM CST

SHE:002581 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
335.89274.74355.66425.78356.18397.44
Other Revenue
0.070.074.754.010.95.27
335.96274.81360.41429.79357.08402.71
Revenue Growth
87.98%-23.75%-16.14%20.36%-11.33%45.47%
Cost of Revenue
269.36152.9287.6793.2976.6485.83
Gross Profit
66.6121.89272.74336.5280.44316.88
Selling, General & Admin
227.22269.38336.65453.3426.21477.76
Research & Development
12.318.8725.3759.827.2938.44
Other Operating Expenses
13.056.16.316.786.246.83
Operating Expenses
269.91311.4363.6492.32456.02520.83
Operating Income
-203.31-189.51-90.86-155.81-175.57-203.95
Interest Expense
-1.61-1.12-0.18-9.06-9.41-6.88
Interest & Investment Income
3.1921.167.28174.463.023.75
Earnings From Equity Investments
----217.45471.94
Currency Exchange Gain (Loss)
-0-00-0-0.01
Other Non Operating Income (Expenses)
-5.540.180.28-9.880.22-6.68
EBT Excluding Unusual Items
-207.27-169.35-23.49-0.2935.72258.18
Gain (Loss) on Sale of Investments
-8.07--18.65---
Gain (Loss) on Sale of Assets
0.83.771.16-6.330.05-0.15
Asset Writedown
-21.35-20.24-69.64-293.88-13.61-0.48
Legal Settlements
---33.27--15.49-
Other Unusual Items
9.0810.28-2.29-12.766.0521.05
Pretax Income
-226.81-175.53-146.18-313.2512.72278.6
Income Tax Expense
-7.31-14.7-3.348.8913.58-0.09
Earnings From Continuing Operations
-219.49-160.83-142.84-322.14-0.86278.69
Minority Interest in Earnings
35.3944.555.52-10.32-13.82-7.69
Net Income
-184.11-116.28-137.31-332.46-14.68271
Net Income to Common
-184.11-116.28-137.31-332.46-14.68271
Net Income Growth
------
Shares Outstanding (Basic)
660660660660658660
Shares Outstanding (Diluted)
660660660660658660
Shares Change
-0.14%-0.04%0.01%0.22%-0.21%-0.00%
EPS (Basic)
-0.28-0.18-0.21-0.50-0.020.41
EPS (Diluted)
-0.28-0.18-0.21-0.50-0.020.41
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-238.81-433.43-15.56-40.82-85.95-106.86
Free Cash Flow Per Share
-0.36-0.66-0.02-0.06-0.13-0.16
Gross Margin
19.82%44.36%75.67%78.30%78.54%78.69%
Operating Margin
-60.52%-68.96%-25.21%-36.25%-49.17%-50.64%
Profit Margin
-54.80%-42.31%-38.10%-77.35%-4.11%67.29%
Free Cash Flow Margin
-71.08%-157.72%-4.32%-9.50%-24.07%-26.53%
EBITDA
-168.39-151.92-49.7-87.43-110.63-144.38
EBITDA Margin
-50.12%-55.28%-13.79%-20.34%-30.98%-35.85%
D&A For EBITDA
34.9237.5941.1668.3964.9559.57
EBIT
-203.31-189.51-90.86-155.81-175.57-203.95
EBIT Margin
-60.52%-68.96%-25.21%-36.25%-49.17%-50.64%
Effective Tax Rate
----106.75%-
Revenue as Reported
335.96274.81360.41429.79357.08402.71